Literature DB >> 24092613

Targeting hyperglycaemia with anti-obesity drugs: time for a paradigm shift?

Andrew J Krentz1, Marcus Hompesch.   

Abstract

Mesh：

Substances：

Year:  2013        PMID： 24092613     DOI： 10.1007/s40265-013-0123-2

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  22 in total

1.  Rosiglitazone: trials, tribulations and termination.

Authors:  Andrew J Krentz
Journal:  Drugs       Date:  2011-01-22       Impact factor: 9.546

2.  Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.

Authors:  Patrick M O'Neil; Steven R Smith; Neil J Weissman; Meredith C Fidler; Matilde Sanchez; Jinkun Zhang; Brian Raether; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2012-03-16       Impact factor: 5.002

3.  Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.

Authors:  André J Scheen; Nick Finer; Priscilla Hollander; Michael D Jensen; Luc F Van Gaal
Journal:  Lancet       Date:  2006-11-11       Impact factor: 79.321

4.  Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women.

Authors:  Steven R Smith; Warren A Prosser; David J Donahue; Michael E Morgan; Christen M Anderson; William R Shanahan
Journal:  Obesity (Silver Spring)       Date:  2008-12-04       Impact factor: 5.002

Review 5.  Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.

Authors:  E W Chan; Y He; C S L Chui; A Y S Wong; W C Y Lau; I C K Wong
Journal:  Obes Rev       Date:  2013-01-21       Impact factor: 9.213

6.  Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.

Authors:  S Jacob; M Rabbia; M K Meier; J Hauptman
Journal:  Diabetes Obes Metab       Date:  2009-01-22       Impact factor: 6.577

Review 7.  Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.

Authors:  Stefanie C Nigro; Darren Luon; William L Baker
Journal:  Curr Med Res Opin       Date:  2013-05-10       Impact factor: 2.580

Review 8.  Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Authors:  Silvio E Inzucchi; Richard M Bergenstal; John B Buse; Michaela Diamant; Ele Ferrannini; Michael Nauck; Anne L Peters; Apostolos Tsapas; Richard Wender; David R Matthews
Journal:  Diabetes Care       Date:  2012-04-19       Impact factor: 19.112

Review 9.  Treating the obese diabetic.

Authors:  Julia Kenkre; Tricia Tan; Stephen Bloom
Journal:  Expert Rev Clin Pharmacol       Date:  2013-03       Impact factor: 5.045

10.  Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum.

Authors:  Itamar Raz; Matthew C Riddle; Julio Rosenstock; John B Buse; Silvio E Inzucchi; Philip D Home; Stefano Del Prato; Ele Ferrannini; Juliana C N Chan; Lawrence A Leiter; Derek Leroith; Ralph Defronzo; William T Cefalu
Journal:  Diabetes Care       Date:  2013-06       Impact factor: 19.112
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.